I-3-Indoleacetonitrile CAS 771-51-7 Ukuhlanzeka >99.0% (HPLC) Isithombe Esifakiwe Sefektri Sekhwalithi Ephezulu

I-3-Indoleacetonitrile CAS 771-51-7 Ukuhlanzeka >99.0% (HPLC) Ifektri Yekhwalithi Ephezulu

Incazelo emfushane:

Igama Lekhemikhali: 3-Indoleacetonitrile

CAS: 771-51-7

Ubumsulwa: >99.0% (HPLC)

Ukubukeka: Impushana Ephuzi Okukhanyayo ukuya Kunsundu Okhanyayo

Ikhwalithi Ephezulu, Ukukhiqizwa Kwezohwebo

E-Mail: alvin@ruifuchem.com

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

I-Shanghai Ruifu Chemical Co., Ltd. ingumkhiqizi oholayo nomphakeli we-3-Indoleacetonitrile (CAS: 771-51-7) enekhwalithi ephezulu, ukukhiqizwa kwezentengiso.Wamukelekile eku-odeni.

Chemical Properties:

Igama Lekhemikhali	3-Indoleacetonitrile
Omqondofana	Indole-3-Acetonitrile;2-(1H-Indol-3-yl)i-acetonitrile
Inombolo ye-CAS	771-51-7
Inombolo yeCAT	I-RF-PI1602
Isimo Sesitoko	Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani
I-Molecular Formula	I-C10H8N2
Isisindo samangqamuzana	156.19
I-Melting Point	33.0~36.0℃ (okhanyisiwe)
Ukuminyana	1.1566
Ukuncibilika	I-Soluble ku-Methanol (Cishe Ukungafihli)
Ibhrendi	I-Ruifu Chemical

Imininingwane:

Into	Imininingwane
Ukubukeka	Impushana Ephuzi Ngokukhanyayo kuya Kuphuphu Olunsundu Okhanyayo
Ukuhlanzeka / Indlela Yokuhlaziya	>99.0% (HPLC)
Ukulahlekelwa Ekumisweni	<1.00%
Ukungcola Okukodwa	<0.50%
Ukungcola Okuphelele	<1.00%
1 H NMR Spectrum	Ihambisana Nesakhiwo
Izinga Lokuhlola	I-Enterprise Standard
Ukusetshenziswa	Pharmaceutical Intermediates

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwezidingo zekhasimende.

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama.

Izinzuzo:

I-FAQ:

Isicelo:

I-3-Indoleacetonitrile (CAS: 771-51-7),Isabela ekulungiseleleni: I-Tryptophan dioxygenase inhibitors pyridyl-ethenyl-indoles njengama-immunomodulators angaba khona e-anticancer;i-histone deacetylase inhibitors;Ama-kinase inhibitors angenzeka;Kv7/KCNQ potassium channel activators;I-Kinesin-Specific MKLP-2 Inhibitor;Izibulala-zinambuzane;Ama-ejenti wokuthwebula umdlavuza we-PET okungenzeka;Ama-Agonists we-Farnesoid X Receptor (FXR) njengokwelashwa kwe-atherosclerosis;I-Butyrylcholinesterase inhibitors;I-Necroptosis inhibitors.